

USAID and WHO-led consultation: February 2022









## NAMIBIA USAID-LED CONSULTATION SUMMARY (MOHSS, WHO, PEPFAR)

GUIDING QUESTION	SUMMARY
PERCEPTIONS OF THE RING	Available efficacy data shows the ring reduces HIV risk by only 48%.
	<ul> <li>Participants expressed uncertainty about the use of the ring by adolescents.</li> </ul>
	<ul> <li>The resources needed to optimally implement and sustain the ring are not available.</li> </ul>
RING PLANS & CONSIDERATIONS	The ring was included in the HIV clinical guidelines in 2021 and added to the NEMLIST (Namibia Essential Medicines List).
	<ul> <li>An implementation plan is under way. PrEP ring implementation was projected to begin mid-2022 subject to the availability of funds to procure the rings.</li> </ul>
WITHDRAWAL EFFECT	<ul> <li>IPM's withdrawal of the ring's NDA from the US FDA does not impact Namibia's plans for ring rollout.</li> </ul>
	WHO's recommendation is most important
	The ring's NDA was not withdrawn over safety or efficacy concerns.
ADDITIONAL INFORMATION NEEDED	<ul> <li>No more information is needed. The ring is already included in Namibia's HIV clinical guidelines.</li> </ul>